Table 2.
Baseline characteristics of patients included in the pharmacokinetic analysis
| Treatment | |||
|---|---|---|---|
| Characteristic | Mericitabine 500 mg (n = 14) | Mericitabine 1000 mg (n = 59) | Mericitabine placebo (n = 35) |
| Male gender [n (%)] | 7 (50.0) | 40 (67.8) | 24 (68.6) |
| Mean age [years (range)] | 48 (24–59) | 47 (19–62) | 47 (20–65) |
| Mean weight [kg (range)] | 80.9 (51.0–110.7) | 81.2 (53.2–108.4) | 82.2 (53.0–129.7) |
| Mean body mass index [kg m−2 (range)] | 27.4 (18.7–34.2) | 27.0 (20.1–36.1) | 26.8 (18.7–35.1) |
| Mean creatinine clearance [ml min−1 (range)] | 128 (74–205) | 120 (69–216) | 122 (64–266) |